20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
13:01 , May 25, 2018 |  BioCentury  |  Product Development

Patients at the core

With excitement mounting for the seven hemophilia gene therapies in the clinic, the National Hemophilia Foundation wanted to avoid a scenario in which patients, physicians and payers had no good way to compare them. The...
00:36 , May 25, 2018 |  BC Innovations  |  Product R&D

Peptides step up

New screening platforms and synthetic approaches could finally solve some of the longstanding hurdles to turning antimicrobial peptides into therapeutic candidates to combat antibacterial resistance, overcoming their history of limited clinical efficacy, systemic toxicity and...
22:10 , Jan 31, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection Cell culture, patient sample and mouse studies identified a CAMP-based antibacterial peptide that could help treat multidrug-resistant (MDR) bacterial infections. Chemical synthesis and bacterial viability assays of CAMP analogs yielded a peptide...
23:54 , Aug 7, 2017 |  BC Extra  |  Company News

Management tracks: Pfenex, Alvotech, uniQure

Biosimilars company Pfenex Inc. (NYSE-M:PFNX) named Evert Schimmelpennink CEO, president and secretary. He succeeds interim CEO Patrick Lucy, who will continue as CBO. Rasmus Rojkjaer was named CEO at biosimilar company Alvotech ehf (Reykjavik, Iceland),...
03:26 , Jun 3, 2017 |  BioCentury  |  Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
12:54 , Mar 15, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Cationic liposomes could be used for intradermal delivery of cancer vaccines. Liposomes composed of cationic 1,2-dioleoyl-3-(trimethyammonium) propane and neutral 1,2-dioleoyl-sn-glycero-3-phosphocholine were loaded with 1 nM of synthetic tumor antigen peptides and 0.5-1 µg...
19:01 , Feb 24, 2017 |  BC Week In Review  |  Company News

Vedanta partners with Stanford and Leiden for microbiome research

Vedanta partnered separately with Stanford's School of Medicine and Leiden's Medical Center to explore the microbiome's response in various diseases. Vedanta and Stanford will analyze how the gut microbiome changes in children with food allergies...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Company News

Bellicum, Leiden University Medical Center deal

Bellicum and the center partnered to discover and validate high-affinity T cell receptor (TCR) candidates to treat cancer. The biotech, which will provide its CaspaCIDe switch technology, will have exclusive, worldwide rights to compounds discovered...
07:00 , May 16, 2016 |  BioCentury  |  Emerging Company Profile

EMT interrupted

Oncodrone B.V. is developing a small molecule that can disrupt the epithelial-mesenchymal transition to prevent tumor cells from gaining invasive and malignant properties. The biotech plans to develop the compound for aggressive tumors such as...